These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19305760)

  • 1. The effect of evidence-based drug coverage policies on pharmaceutical r&d: a case study from british columbia.
    Morgan S; Cunningham C
    Healthc Policy; 2008 Feb; 3(3):e128-53. PubMed ID: 19305760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of evidence-based drug coverage policies on pharmaceutical r&d: a case study from british columbia.
    Morgan S; Cunningham C
    Healthc Policy; 2008 Feb; 3(3):54-63. PubMed ID: 19305768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Navigating the nexus between British Columbia's public consumption and decriminalization policies of illegal drugs.
    Ali F; Law J; Russell C; Crépault JF; Goulão JC; Lock K; Rehm J
    Health Res Policy Syst; 2024 May; 22(1):60. PubMed ID: 38783308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Income-based drug coverage in British Columbia: the impact on private and public expenditures.
    Morgan S; Yan L
    Healthc Policy; 2006 Nov; 2(2):e129-53. PubMed ID: 19305696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Income-Based Drug Coverage in British Columbia: Lessons for BC and the Rest of Canada.
    Morgan S; Evans RG; Hanley GE; Caetano PA; Black C
    Healthc Policy; 2006 Nov; 2(2):115-27. PubMed ID: 19305708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia.
    Grootendorst P; Stewart D
    Health Econ; 2006 Jul; 15(7):735-42. PubMed ID: 16498702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia.
    Marshall JK; Grootendorst PV; O'Brien BJ; Dolovich LR; Holbrook AM; Levy AR
    CMAJ; 2002 Jun; 166(13):1655-62. PubMed ID: 12126319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pricing of alcohol in Canada: A comparison of provincial policies and harm-reduction opportunities.
    Giesbrecht N; Wettlaufer A; Thomas G; Stockwell T; Thompson K; April N; Asbridge M; Cukier S; Mann R; McAllister J; Murie A; Pauley C; Plamondon L; Vallance K
    Drug Alcohol Rev; 2016 May; 35(3):289-97. PubMed ID: 26530717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health policy versus industrial policy in the pharmaceutical sector: the case of Canada.
    Vandergrift M; Kanavos P
    Health Policy; 1997 Sep; 41(3):241-60. PubMed ID: 10170092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.
    Schneeweiss S; Soumerai SB; Glynn RJ; Maclure M; Dormuth C; Walker AM
    CMAJ; 2002 Mar; 166(6):737-45. PubMed ID: 11944760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brown v. British Columbia (Minister of Health).
    Canada. British Columbia. Supreme Court
    Dom Law Rep; 1990 Jan; 66():444-69. PubMed ID: 12041076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes-based drug coverage in British Columbia.
    Morgan S; Bassett K; Mintzes B
    Health Aff (Millwood); 2004; 23(3):269-76. PubMed ID: 15160825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.
    Schneeweiss S; Soumerai SB; Maclure M; Dormuth C; Walker AM; Glynn RJ
    Clin Pharmacol Ther; 2003 Oct; 74(4):388-400. PubMed ID: 14534526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantifying components of drug expenditure inflation: the British Columbia seniors' drug benefit plan.
    Morgan SG
    Health Serv Res; 2002 Oct; 37(5):1243-66. PubMed ID: 12479495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Income-based drug coverage in british columbia: towards an understanding of the policy.
    Morgan S; Coombes M
    Healthc Policy; 2006 Nov; 2(2):92-108. PubMed ID: 19305707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the economic value of British Columbia's domestic cannabis market: implications for provincial cannabis policy.
    Werb D; Nosyk B; Kerr T; Fischer B; Montaner J; Wood E
    Int J Drug Policy; 2012 Nov; 23(6):436-41. PubMed ID: 23085258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Return on Investment of a Province-Wide Quality Improvement Initiative for Reducing In-Hospital Sepsis Rates and Mortality in British Columbia, Canada.
    Khowaja AR; Willms AJ; Krause C; Carriere S; Ridout B; Kennedy C; Young E; Mitton C; Kissoon N; Sweet DD
    Crit Care Med; 2022 Apr; 50(4):e340-e350. PubMed ID: 34593705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating reference-based pricing: initial findings and prospects.
    Narine L; Senathirajah M; Smith T
    CMAJ; 1999 Aug; 161(3):286-8. PubMed ID: 10463052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia.
    Morgan SG; Agnew JD; Barer ML
    Health Policy; 2004 Jun; 68(3):299-307. PubMed ID: 15113641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada.
    Marshall DA; Willison DJ; Grootendorst P; LeLorier J; Maclure M; Kulin NA; Sheehy OE; Warren L; Sykora K; Rahme E
    Health Policy; 2007 Nov; 84(1):1-13. PubMed ID: 17570558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.